Ceretrieve
Founded 2017 · 17 employees on LinkedIn · 4 known investors
Ceretrieve Ltd. develops neurointerventional medical devices, including distal access catheters, thrombectomy devices, and related accessories, working with physicians to improve device performance and patient outcomes. It serves the interventional physician and neurovascular care market.
Also known as Ceretrieve Ltd.
Investors · 4
Also in the syndicate · 3
Company profile
researched Aug 2026Ceretrieve Ltd. is an Israeli medical device company developing neurointerventional devices for the treatment of ischemic stroke. Its pipeline covers distal access catheters, thrombectomy devices and related accessories, with a focus on improving device maneuverability, stability, reliability and overall performance in neurointerventional procedures.
The company's lead concept is a neurothrombectomy system built around a next-generation aspiration catheter with a proprietary large-bore self-expandable soft tip and a tip closure mechanism. The tip expands from 6F to the size of the clot to generate aspiration force sufficient to extract the clot in one piece on the first pass, capturing the clot inside the expandable tip to restore blood flow while limiting distal embolization, and incorporating integrated embolic protection. Device design is carried out in collaboration with practicing physicians to target specific limitations of the current standard of care.
Ceretrieve is a portfolio company of The Trendlines Group. Its team includes CEO and director Maysa Mustafa, chairman Amir Belson, M.D., co-founder and director Dr. Ronen Jaffe, CTO Yuval Zipori, and Trendlines CEO Barak Singer on the board, alongside engineering, manufacturing, quality assurance/regulatory and clinical affairs staff. A scientific advisory board includes Prof. Raul Nogueira, Dr. Shady Jahshan and Prof. Serdar Geyik.
Founding story
Dr. Ronen Jaffe is listed as a co-founder and director of the company.
Business model
Ceretrieve develops proprietary neurointerventional devices, protected by an IP portfolio, intended for use by interventional physicians treating ischemic stroke. It is a development-stage medical device company that was working toward first-in-human clinical studies and a go-to-market plan as of the 2021 funding announcement.
Traction
As of the January 2021 funding announcement, the company had designed and developed its aspiration catheter and planned first-in-human clinical studies for 2021.
Latest developments
A startup platform listing last modified in November 2025 describes Ceretrieve as a Round A-stage digital health and medical device company in Yokne'am Illit developing a neurothrombectomy system with integrated embolic protection.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Ceretrieve targets the thrombectomy device market; a 2021 company press release cited third-party market data valuing the global thrombectomy devices market at USD 1.12 billion in 2020, growing at a 7.4% CAGR to an estimated USD 1.6 billion by 2025.
Ceretrieve positions its devices around specific proprietary features: an aspiration catheter with a large-bore self-expandable soft tip that widens from 6F to clot size, a tip closure mechanism and integrated embolic protection, intended to enable complete clot removal on the first pass while preventing clot dislodgement without compromising trackability. The company states its products are protected by an IP portfolio.
Technology
An aspiration-based neurothrombectomy system whose catheter uses a large-bore self-expandable soft tip that expands from 6F to the clot diameter, plus a tip closure mechanism and integrated embolic protection, so that the clot is ingested and removed intact in a single pass. The broader pipeline includes distal access catheters and related accessories.
Go-to-market
Interventional physicians and neurovascular care providers treating ischemic stroke patients.
Geography
The company is based in Israel, with an address at 6 HaYetsira St., Yokne'am Illit; a 2021 press release listed Misgav, Israel as its location.
History
Ceretrieve is a portfolio company of The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY), an Israel- and Singapore-based investment group focused on medical and agrifood technologies. The company closed a $1.5 million financing at the end of 2020 and appointed Amir Belson, M.D. as chairman in January 2021, with the proceeds intended to advance first-in-human clinical studies planned for 2021. A startup directory listing dated November 2025 records the company at Round A stage.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
2 people who came through Ceretrieve went on to found or lead other companies.
Timeline · 1
launches, deals, and filingsCeretrieve appointed serial medical device entrepreneur Amir Belson, M.D. as chairman, following the close of a $1.5 million funding round. Belson previously founded Neoguide Systems, Vascular Pathways and Zipline Medical.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 7
primary sources listed
- Ceretrieveceretrieve.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Ceretrieve do?
- Israeli medical device company developing neurothrombectomy and distal access catheter systems for ischemic stroke treatment.
- Who are Ceretrieve's investors?
- Ceretrieve's investors include Trendlines Group.